ArticleChemMedChem2017
Medicinal Chemistry Profiling of Monocyclic 1,2-Azaborines.
Article in ChemMedChem, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Boron-Based Bioisosteres in Medicinal Chemistry: Advances in Heterocycles and Therapeutic.ChemMedChem · 2026Review
- Copper-Catalyzed Asymmetric Hydroboration of Alkynes to C-N Axially Chiral Azaborines via Dynamic Kinetic Resolution.Angewandte Chemie (International ed. in English) · 2026Article
- The acylative kinetic resolution of 1,2-azaborine naphthols.Chemical science · 2026Article
- A Catalyst-Controlled Divergent Rearomatization of BN-Benzvalene.Journal of the American Chemical Society · 2026Article
- Catellani-Inspired BN-Aromatic Expansion: A Versatile Tool toward π-Extended 1,2-Azaborines with Tunable Photosensitizing Properties.Journal of the American Chemical Society · 2026Article
- Positional Isomerization of 1,2-Azaborine through BN-Benzvalene.Journal of the American Chemical Society · 2026Article
- Organocatalysed three-component modular synthesis of BN isosteres and BN-2,1-azaboranaphthalenes via Wolff-type rearrangement.Nature chemistry · 2026Article
- Core diversification using 1,2-oxaborines as a versatile molecular platform.Nature chemistry · 2026Article
- Boron-containing anticancer agents: a target-centric review of structure-activity relationships and clinical pipeline.Archives of pharmacal research · 2025Review
- Recent Advancements in the Diversification and Applications of Boron-Containing Compounds in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Novel Azaborine-Based Inhibitors of Histone Deacetylases (HDACs).Molecules (Basel, Switzerland) · 2025Article
- Synthesis of Chiral δ-Aminoboronic Esters by Enantioselective Hydrogenation of 1,2-Azaborines.Angewandte Chemie (International ed. in English) · 2025Article
- Boron-Nitrogen-Containing Benzene Valence Isomers.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Rapid and Modular Access to Multifunctionalized 1,2-Azaborines via Palladium/Norbornene Cooperative Catalysis.Journal of the American Chemical Society · 2024Article
- Modular synthesis of 1,2-azaborines via ring-opening BN-isostere benzannulation.Nature chemistry · 2024Article
- Synthesis and crystal structure of bis-(9-mesityl-9,10-di-hydro-10-aza-9-borabenzo[Acta crystallographica. Section E, Crystallographic communications · 2023Article
- Solvatochromic and Aggregation-Induced Emission Active Nitrophenyl-Substituted Pyrrolidinone-Fused-1,2-Azaborine with a Pre-Twisted Molecular Geometry.Journal of materials chemistry. C · 2023Article
- The aromatic Claisen rearrangement of a 1,2-azaborine.Organic & biomolecular chemistry · 2023Article
- A rapid construction of 1,3,2-benzodiazaborininones [R-B(aam)] from boronic acids and anthranilamides.RSC advances · 2023Article
- Synthesis of BN-Polyarenes by a Mild Borylative Cyclization Cascade.Organic letters · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The first examples of biologically active monocyclic 1,2-azaborines have been synthesized and demonstrated to exhibit not only improved in vitro aqueous solubility in comparison with their corresponding carbonaceous analogues, but in the context of a CDK2 inhibitor, also improved biological activity and better in vivo oral bioavailability. This proof-of-concept study establishes the viability of monocyclic 1,2-azaborines as a novel pharmacophore with distinct pharmacological profiles that can help address challenges associated with solubility in drug development research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.